Table 3.

Summary of the current literature on CHD1L deregulation in solid cancers

Cancer	Deregulation	Downstream targets	Phenotypic effect	clinical impact	References
HCC	CHD1L↑	P53↓, p21↓, cyclinE↑, CDK2↑	G1/S phase transition↑, apoptosis↓, proliferation↑		[1]
	CHD1L↑	Nur77↓	apoptosis↓		[18]
	CHD1L↑	ARHGEF9↑, Cdc42↑	migration↑, invasion↑, metastasis↑		[14]
	CHD1L↑	TCTP↑, Cdc25c↓, Cdk1↓	Mitotic progression↑, aneuploidy↑		[15]
	CHD1L↑	SPOCK1↑, Akt↑	apoptosis↓, invasion↑, metastasis↑		[16]
	CHD1L↑	NTKL↑	cell growth↑, colony formation↑, G1/S transition↑		[17]
	CHD1L↑	NA		Poor Prognosis	[21]
Ovarian carcinoma	CHD1L↑	NA	metastasis↑	Prognostic biomarker	[23]
	CHD1L↑	METAP2↑	invasion↑, metastasis↑		[19]
Gastric cancer	CHD1L↑	NA		Prognostic biomarker	[22]
Colorectal carcinoma	CHD1L↑	NA	G1/S phase transition↑, apoptosis↓	Prognostic biomarker	[24]
Bladder cancer	CHD1L↑	NA		Prognostic biomarker	[25]
Breast cancer	CHD1L↑	NA		Prognostic biomarker	[27]
	CHD1L↑	MDM2↑, p53↓	Cell cycle↑, cell motility↑		[63]
	CHD1L↑	PI3K↑, Akt↑, ARK5↑, mTOR↑, MMP2↑, MMP9↑	chemotaxis↑, invasion↑, lung colonization↑		[4]
Nasopharyageal carcinoma	CHD1L↑	NA		Prognostic biomarker	[27]
Glioma	CHD1L↑	PCNA↑, β-catenin ↓, cyclinD1↑, p53↓, p21↓, cyclinE↑, Cdk2↑, c-capase3↓, Bcl2↑	G1/S phase transition↑, proliferation↑, apoptosis↓, migration↑, invasion↑		[64]
NSCLC	CHD1L↑	NA		Prognostic biomarker	[12]
	CHD1L↑	ABCB1↑, c-Jun↑, NF-kB↑	Cisplatin resistance		[66]
Myeloma	CHD1L↑	c-capase9↓, capase3↓	Anti-apoptosis, cell adhesion-mediated drug resistance↑		[6]
Pancreatic cancer	CHD1L↑	β-catenin↑	Cell proliferation↑	Poor prognosis	[65]
Esophageal carcinoma	CHD1L↑	NA	proliferation↑, apoptosis↓, metastasis↑, invasion↑	Poor prognosis	[28]
	CHD1L↑	PI3K/Akt pathway↑	viability↑, apoptosis↓, cisplatin cytotoxicity↓, glycolysis↑		[67]
Cholangiocarcinoma	CHD1L↑	hMLH1↓		Prognostic biomarker	[103]
	CHD1L↑	P53↓, cyclinD1↑, CDK2↑, E-cadherin↓, N-cadherin↑, Vimentin↑	EMT↑, G1/S transition↑, Cell proliferation↑	Poor prognosis	[20]